Clarus Therapeutics Holdings, Inc.
CRXWQ
Other OTC0.00
USD
- -
- -
CIK
0001817944
Return %
Stock
S&P500
1Y
-99.81
26.53
3Y
-99.97
76.60
5Y
-99.97
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- CIK
- 0001817944
- Similar Companies
- Business
- Clarus Therapeutics Holdings, Inc. (CRXWQ) operates as a pharmaceutical company focused on the development and commercialization of androgen-based therapies, including oral testosterone replacement products such as JATENZO, a softgel formulation of testosterone undecanoate indicated for hypogonadal men; licensing agreements for androgen therapies targeting inflammatory breast disease and certain breast cancers with HavaH Therapeutics, and metabolic treatments for CoQ10 deficiency conditions with McGill University technology. Founded in 2003 and headquartered in Northbrook, Illinois, the company previously pursued therapies for men's health and orphan indications through its wholly-owned subsidiary Clarus Therapeutics, Inc., with operations centered in the United States. In September 2022, Clarus filed for voluntary Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware (Case No. 22-10845) to facilitate a structured auction and sale of its primary asset JATENZO; Tolmar, Inc. emerged as the successful bidder in October 2022, acquiring all rights to JATENZO and related assets following court approval, with the plan of liquidation becoming effective on February 28, 2023, resulting in the company ceasing active operations.